首页> 美国卫生研究院文献>European Journal of Hospital Pharmacy >Impact of the Council of Europe Resolution on quality and safety assurance requirements for medicinal products prepared in pharmacies for the special needs of patients
【2h】

Impact of the Council of Europe Resolution on quality and safety assurance requirements for medicinal products prepared in pharmacies for the special needs of patients

机译:欧洲委员会决议对药房根据患者特殊需要制备的药品的质量和安全保证要求的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Introduction and objectiveThe regulation of pharmacy preparations, especially for standards for quality assurance and safety, is not harmonised across Europe and falls under the national competencies of individual states. There are concerns about quality control and safety for the medicinal products made in pharmacies, which is widespread in European countries. There are, however, good reasons to continue this practice, which is able to tailor preparations to the specific needs of a particular patient or patient group and to provide a supplementary source of supply when an industrially manufactured product, which is authorised for marketing is not available or when there are temporary shortages of licensed medicines. In seeking to provide guidelines for legislation and acting on the advice of an expert group dealing in pharmaceutical practices, the Committee of Ministers of the Council of Europe passed a resolution in 2011. The Council of Europe Resolution provides authorities and pharmacists with the means to reinforce safety measures for medicinal products prepared in pharmacies and to harmonise quality assurance and safety standards. It dealt with aspects of pharmacy preparation such as quality standards for preparation and distribution, marketing authorisation, product dossiers, labelling, reporting, and safety. In 2013 and 2014 the Committee of Experts carried out a survey to evaluate the impact of the resolution within a cross section of member states. The objectives of this study were both to monitor the extent to which the recommendations had been enshrined in national legislation and also to understand current differences in legislation and practice between the member states.
机译:简介和目的药房制剂的法规,尤其是质量保证和安全标准的法规,在整个欧洲范围内并不统一,属于各州的国家权限。药房生产的药用产品存在质量控制和安全性的问题,这种情况在欧洲国家十分普遍。但是,有充分的理由继续这种做法,这种做法能够根据特定患者或患者群体的具体需求量身定制制剂,并在没有授权销售的工业生产产品被提供时提供补充的货源。可用或当许可药品暂时短缺时。欧洲委员会部长委员会在寻求为立法提供指导方针并根据制药实践专家组的建议采取行动时,于2011年通过了一项决议。欧洲委员会决议为当局和药剂师提供了强化手段药房配制的药品的安全措施,以协调质量保证和安全标准。它涉及药房准备工作的各个方面,例如准备和分配的质量标准,市场授权,产品档案,标签,报告和安全性。 2013年和2014年,专家委员会进行了一项调查,以评估该决议在各成员国中的影响。这项研究的目的既是为了监测建议在国家立法中的体现程度,也是为了了解成员国之间在立法和实践方面的当前差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号